News
Roche's star MS medicine Ocrevus wins EU approval | Reuters
www.reuters.com
The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its...
European Commission Grants Approval for Mavenclad (Cladribine...
www.ots.at
Aug 25, · "This is an exciting moment and one that will change the way we treat MS," said Gavin Giovannoni, Professor of Neurology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London. "MAVENCLAD® is a selective immune reconstitution therapy (SIRT) which simplifies treatment administration, by giving patients just ...
Merck Serono Announces CHMP Opinion for Cladribine Tablets in MS
www.finanznachrichten.de
GENEVA, September 24, PRNewswire Merck Serono is Committed to Making Cladribine Tablets Available to MS Patients in Europe and is Evaluating all...
Mavenclad – EU-Erstzulassung von oraler Kurzzeittherapie bei...
www.gelbe-liste.de
Auch Gavin Giovannoni, Professor für Neurologie am Barts and The London School of Medicine and Dentistry der Queen Mary University of London äußerst sich optimistisch zur Marktzulassung von Mavenclad: „Dies ist ein aufregender Moment, der zudem die …
sortiert nach Relevanz / Datum